NOTE: April 24 is World Malaria Day, and IDRI is taking part in a local event to discuss how our innovations are helping stop malaria. We work with a variety of collaborators around the world, providing our adjuvants for use in malaria vaccine candidates.
Imagine a tool that could enable new vaccines to be developed or existing vaccines to be more widely available. Such tools do exist – they are called adjuvants, and they are a critical component of modern vaccines.
Adjuvants are substances added to vaccines that enhance the ability of antigens to stimulate the body’s immune response. They can:
- Enhance and/or increase duration of vaccine antigen-specific antibody and cellular immune responses
- Broaden vaccine efficacy against drifted pathogen strains
- Reduce the amount of vaccine or the number of immunizations needed
However, adjuvants can only become that tool if they are formulated appropriately. Significantly different immune responses may be elicited by the same adjuvant if it is formulated in distinct ways. Formulation promotes manufacturability, stability, safety, bioactivity and compatibility with vaccine antigens and administration routes. The correct formulation of adjuvants then can allow us to choose the right tool for the job, making a vaccine more effective. (more…)